Piclamilast
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.229.714 |
| Chemical and physical data | |
| Formula | C18H18Cl2N2O3 |
| Molar mass | 381.25 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Piclamilast (RP 73401), is a selective PDE4 inhibitor.[1] It is comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. It is a second generation compound that exhibits structural functionalities of the PDE4 inhibitors cilomilast and roflumilast. The structure for piclamilast was first elucidated in a 1995 European patent application.[2] The earliest mention of the name "piclamilast" was used in a 1997 publication.[3]
Pharmacology
Piclamilast functions through the selective inhibition of the four PDE4 isoforms (PDE4A-D). It shows no inhibition of the other PDEs. The PDE4 isoforms are especially important to inflammatory and immunomodulatory cells. They are the most common PDE in inflammatory cells such as mast cells, neutrophils, basophils, eosinophils, T lymphocytes, macrophages, and structural cells such as sensory nerves and epithelial cells. PDE4 hydrolyzes cyclic adenosine monophosphate (cAMP) to inactive adenosine monophosphate (AMP). Inhibition of PDE4 blocks hydrolysis of cAMP thereby increasing levels of cAMP within cells. cAMP suppresses the activity of immune and inflammatory cells.
PDE4 inhibition in an induced chronic lung disease murine model was shown to have anti-inflammatory properties, attenuate pulmonary fibrin deposition and vascular alveolar leakage, and prolong survival in hyperoxia-induced neonatal lung injury. A study of PDE4 inhibition in a murine model of allergic asthma showed that piclamilast significantly improves the pulmonary function, airway inflammation and goblet cell hyperplasia.[4][5]
Side effects
Vomiting is the most commonly cited side effect of piclamilast. It has proven difficult to separate the emetic side effects from the therapeutic benefits of several PDE4 inhibitors, including piclamilast.[6]
References
- ^ Beeh KM, Beier J, Lerch C, Schulz AK, Buhl R (2004). "Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients". Lung. 182 (6): 369–77. doi:10.1007/s00408-004-2518-z. PMID 15765929. S2CID 2558906.
- ^ EP expired 0497564, Ashton, Michael John; Cook, David Charles & Fenton, Garry et al., "Benzamides", published 1992-08-05, assigned to Rhone-Poulenc Rorer Ltd.
- ^ Souness JE, Houghton C, Sardar N, Withnall MT (June 1997). "Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer". British Journal of Pharmacology. 121 (4): 743–50. doi:10.1038/sj.bjp.0701200. PMC 1564751. PMID 9208143.
- ^ Sun JG, Deng YM, Wu X, Tang HF, Deng JF, Chen JQ, et al. (October 2006). "Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma". Life Sciences. 79 (22): 2077–85. doi:10.1016/j.lfs.2006.07.001. PMID 16875702.
- ^ de Visser YP, Walther FJ, Laghmani EH, van Wijngaarden S, Nieuwland K, Wagenaar GT (March 2008). "Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury". The European Respiratory Journal. 31 (3): 633–44. doi:10.1183/09031936.00071307. PMID 18094015.
- ^ Hirose R, Manabe H, Nonaka H, Yanagawa K, Akuta K, Sato S, et al. (November 2007). "Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain". European Journal of Pharmacology. 573 (1–3): 93–9. doi:10.1016/j.ejphar.2007.06.045. PMID 17658510.